News
- News
- Language
- Product
- GORE® BIO-A® Tissue Reinforcement (3)
- GORE® DUALMESH® Biomaterial (1)
- GORE® DUALMESH® PLUS Biomaterial (1)
- GORE® Embolic Filter (2)
- GORE® EXCLUDER® AAA Endoprosthesis (16)
- GORE® Flow Reversal System (3)
- GORE® HELEX Septal Occluder (12)
- GORE® INFINIT Mesh (1)
- GORE® PRECLUDE® Vessel Guard (2)
- GORE® PROPATEN® Vascular Graft (5)
- GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement (1)
- GORE® TAG® Thoracic Endoprosthesis (12)
- GORE® VIABAHN® Endoprosthesis (24)
- GORE® VIABIL® Biliary Endoprosthesis (2)
- GORE® VIATORR® TIPS Endoprosthesis (2)
- GORE-TEX® Stretch Vascular Graft For Vascular Access (1)
- GORE-TEX® Vascular Graft (2)
- GORE® 3D Imaging System (2)
- GORE® ACUSEAL Vascular Graft (1)
- GORE® BIO-A® Fistula Plug (1)
- GORE® DrySeal Sheath (3)
- GORE® HELEX Septal Occluder (11)
- GORE® Hybrid Vascular Graft (4)
- GORE® Septal Occluder (3)
- GORE® TAG® Thoracic Endoprosthesis (12)
- GORE® TAG® Thoracic Endoprosthesis (19)
- GORE® VIABAHN® Endoprosthesis (18)
- GORE® VIABAHN® Endoprothesis (19)
Trauma Indication Press ReleaseConformable GORE® TAG® Thoracic Endoprosthesis
(205 KB, 1 pages, .pdf)
Gore REVISE Study Receives Conditional Approval From FDA
12 July 2007 - Conditional approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with GORE VIABAHN® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates.
12 July 2007 - Conditional approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with GORE VIABAHN® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates.
Rush University Medical Center First to Enroll Patient in the Gore REDUCE Clinical Study for the Indication of Patent Foramen Ovale (PFO) Closure
11 December 2008 - Multi-national trial to demonstrate safety, effectiveness of GORE HELEX Septal Occluder for PFO closure in patients with a history of cryptogenic stroke
11 December 2008 - Multi-national trial to demonstrate safety, effectiveness of GORE HELEX Septal Occluder for PFO closure in patients with a history of cryptogenic stroke
Gore Showcases New Endovascular Repair Simulation Technology at VIVA
18 October 2011 - Physicians Simulate Real Patient Cases Ushering New Era of Procedure Preparation
18 October 2011 - Physicians Simulate Real Patient Cases Ushering New Era of Procedure Preparation
Vascular Surgeons Present Positive Study Results for the GORE PROPATEN® Vascular Graft and Updates to the GORE VIABAHN® Endoprosthesis
17 September 2009 - Physicians report new information at the Society for Vascular Surgery's annual meeting
17 September 2009 - Physicians report new information at the Society for Vascular Surgery's annual meeting
Gore REDUCE Clinical Study Principal Investigators Respond to Recent RESPECT Clinical Trial and PC Trial Results
15 November 2012 - Gore REDUCE Clinical Study Investigators Implored to Continue Enrollment, Drive 'Diligent Continuation of Study'
15 November 2012 - Gore REDUCE Clinical Study Investigators Implored to Continue Enrollment, Drive 'Diligent Continuation of Study'
Gore Receives CE Mark for GORE® PROPATEN® Vascular Graft for Hemodialysis Access
22 February 2011 - Unique Vascular Graft Transcends Mechanical Solutions for Dialysis Access
22 February 2011 - Unique Vascular Graft Transcends Mechanical Solutions for Dialysis Access
Gore receives FDA approval for GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
05 September 2007 - Heparin-Bonded Endoprosthesis for Superficial Femoral Artery Interventions
05 September 2007 - Heparin-Bonded Endoprosthesis for Superficial Femoral Artery Interventions
England National Institute for Health Research Stroke Research Network Adopts Gore REDUCE Clinical Study
19 June 2012 - Study Investigates Device Closure of Patent Foramen Ovale (PFO) in Stroke Reduction.
19 June 2012 - Study Investigates Device Closure of Patent Foramen Ovale (PFO) in Stroke Reduction.
W. L. Gore & Associates Continues its Tradition As One of Nation’s Best Workplaces
25 January 2010 - Company Ranks No. 13 on FORTUNE’S 2010 “100 Best Companies to Work For” List
25 January 2010 - Company Ranks No. 13 on FORTUNE’S 2010 “100 Best Companies to Work For” List
First Patient Enrolled in GORE® Septal Occluder Clinical Study for Atrial Septal Defect
19 October 2012 - Pivotal Multicenter Trial Begins at Duke University, Evaluating Safety and Efficacy of Innovative ASD Closure Device
19 October 2012 - Pivotal Multicenter Trial Begins at Duke University, Evaluating Safety and Efficacy of Innovative ASD Closure Device
W. L. Gore & Associates Continues its Tradition as One of Nation's Best Workplaces
20 January 2011 - Company Earns 14th Consecutive Appearance on FORTUNE’S "100 Best Companies to Work For" List
20 January 2011 - Company Earns 14th Consecutive Appearance on FORTUNE’S "100 Best Companies to Work For" List
Gore Reports First Patient Treated using GORE® C3 Delivery System for GORE® EXCLUDER® AAA Endoprosthesis
11 January 2011 - New medical innovation repositions the future of endovascular repair for abdominal aortic aneurysm
11 January 2011 - New medical innovation repositions the future of endovascular repair for abdominal aortic aneurysm
Gore Reaffirms Commitment to Stroke Study, Launches Online Resource
15 November 2010 - Cardiology and Neurology Investigators Support Continued Study of Patent Foramen Ovale (PFO)
15 November 2010 - Cardiology and Neurology Investigators Support Continued Study of Patent Foramen Ovale (PFO)
Features and BenefitsEXCLUDER® AAA Endoprosthesis 31 mm US Product Availability
(91 KB, 1 pages, .pdf)
First Patient Enrolled in Study Evaluating Performance of Spectranetics Laser Ablation Followed by GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
25 February 2008 - Physician-sponsored study to examine combination therapy for lower limb in-stent restenosis in patients treated for Peripheral Vascular Disease.
25 February 2008 - Physician-sponsored study to examine combination therapy for lower limb in-stent restenosis in patients treated for Peripheral Vascular Disease.
Endovascular Repair of Descending Thoracic Aortic Aneurysm
25 October 2007 - On November 6, 2007, at 3 pm (EST) surgeons and radiologists from the University of Michigan Health System will perform a descending thoracic aortic aneurysm repair with the GORE TAG® Thoracic Endoprosthesis.
25 October 2007 - On November 6, 2007, at 3 pm (EST) surgeons and radiologists from the University of Michigan Health System will perform a descending thoracic aortic aneurysm repair with the GORE TAG® Thoracic Endoprosthesis.
Gore Acquires Intellectual Property of NMT Medical, Inc.
19 October 2011 - CLOSURE I Trial Data May Create Better Clinical Understanding of Patent Foramen Ovale (PFO) in Stroke Patients
19 October 2011 - CLOSURE I Trial Data May Create Better Clinical Understanding of Patent Foramen Ovale (PFO) in Stroke Patients
Gore Receives FDA Approval for Next Generation of Large Diameter GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
21 July 2009 - Improved design now available with lower profile delivery system for use in iliac arteries.
21 July 2009 - Improved design now available with lower profile delivery system for use in iliac arteries.
Improved GORE® DrySeal Sheath with Hydrophilic Coating Allows for Smooth and Minimally Invasive Endovascular Repair
18 December 2012 - Engineered to Increase Sheath Lubricity and Minimize Coating Particulation for Easier Insertion and Removal in Treatment of Patients with AAA and TAA
18 December 2012 - Engineered to Increase Sheath Lubricity and Minimize Coating Particulation for Easier Insertion and Removal in Treatment of Patients with AAA and TAA
Gore Reports First Patient Treated in the US using GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface on a Lower Profile Delivery System
21 March 2011 - Lower profile delivery system provides more options for endoluminal bypass
21 March 2011 - Lower profile delivery system provides more options for endoluminal bypass
Gore Receives FDA Approval for Modification of GORE VIABAHN® Endoprosthesis
17 September 2008 - Manufacturing modification of the only stent-graft approved for treatment of both iliac and superficial femoral arteries.
17 September 2008 - Manufacturing modification of the only stent-graft approved for treatment of both iliac and superficial femoral arteries.
Gore Announces New Configuration of GORE BIO-A® Tissue Reinforcement for Hiatal Hernia Repair
15 June 2008 - Gore adds thinner, more flexible, custom size bioabsorbable product
15 June 2008 - Gore adds thinner, more flexible, custom size bioabsorbable product
Gore Receives CE Mark Approval for Removable GORE® VIABIL® Biliary Endoprosthesis
27 April 2010 - Expanded indication enables stent removal for up to 12 months following implantation for effective treatment of both malignant and benign biliary strictures.
27 April 2010 - Expanded indication enables stent removal for up to 12 months following implantation for effective treatment of both malignant and benign biliary strictures.
Gore Reacts to RESPECT Trial Results
26 October 2012 - Data Calls for Further Research on Transcatheter Patent Foramen Ovale (PFO) Closure
26 October 2012 - Data Calls for Further Research on Transcatheter Patent Foramen Ovale (PFO) Closure
Gore Announces European Availability of Next Evolution of GORE® VIABAHN® Endoprosthesis
19 January 2011 - Lower profile delivery system in Europe provides more options for endoluminal bypass
19 January 2011 - Lower profile delivery system in Europe provides more options for endoluminal bypass
New Clinical Evidence Supporting Efficacy of GORE® PROPATEN® Vascular Graft
19 January 2011 - Jes Lindholt, MD, PhD presented new study data from a Scandinavian clinical trial designed to compare patency rates of the GORE PROPATEN Vascular Graft with standard ePTFE grafts (GORE-TEX® Stretch Vascular Graft).
19 January 2011 - Jes Lindholt, MD, PhD presented new study data from a Scandinavian clinical trial designed to compare patency rates of the GORE PROPATEN Vascular Graft with standard ePTFE grafts (GORE-TEX® Stretch Vascular Graft).
Clinical Investigators Address Confusion Over Study of Patent Foramen Ovale (PFO) in Stroke Patients
13 December 2010 - W. L. Gore & Associates today released the following statement from the Gore REDUCE Clinical Study Principal Investigators on behalf of the Gore REDUCE Clinical Study Steering Committee in response to the recent CLOSURE I results presentation.
13 December 2010 - W. L. Gore & Associates today released the following statement from the Gore REDUCE Clinical Study Principal Investigators on behalf of the Gore REDUCE Clinical Study Steering Committee in response to the recent CLOSURE I results presentation.
First Patient Treated with 25cm Longest LengthGORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface
(106 KB, 1 pages, .pdf)
Gore Receives CE Mark for GORE PRECLUDE® Vessel Guard
06 May 2008 - Distinguished seal allows biomaterial to be used across the European Union
06 May 2008 - Distinguished seal allows biomaterial to be used across the European Union
Gore Receives Approval to Market GORE TAG® Thoracic Endoprosthesis in Japan
03 June 2008 - Expedited Clearance Provides Less Invasive Treatment Alternative for Thoracic Aortic Aneurysms
03 June 2008 - Expedited Clearance Provides Less Invasive Treatment Alternative for Thoracic Aortic Aneurysms
Royal Sussex County Hospital First in the UK to Enroll a Patient in the Gore REDUCE Clinical Study for the Indication of Patent Foramen Ovale (PFO) Closure
01 November 2011 - International study to demonstrate safety, effectiveness of GORE® HELEX® Septal Occluder for PFO closure in patients with a history of cryptogenic stroke
01 November 2011 - International study to demonstrate safety, effectiveness of GORE® HELEX® Septal Occluder for PFO closure in patients with a history of cryptogenic stroke
W. L. Gore & Associates takes on peripheral vascular disease at Vascular Interventional Advances (VIVA) Conference
11 October 2007 - W. L. Gore & Associates recently took part in the fifth annual Vascular Interventional Advances (VIVA) Conference in Las Vegas, where the focus was on new technologies for combating peripheral vascular disease (PVD), also called peripheral arterial disease (PAD).
11 October 2007 - W. L. Gore & Associates recently took part in the fifth annual Vascular Interventional Advances (VIVA) Conference in Las Vegas, where the focus was on new technologies for combating peripheral vascular disease (PVD), also called peripheral arterial disease (PAD).
Gore Receives FDA Approval for New GORE® EXCLUDER® AAA Endoprosthesis Components
14 January 2013 - Expanded Treatment Options for Abdominal Aortic Aneurysms Provide More Patients with Access to Minimally Invasive Endovascular Repair
14 January 2013 - Expanded Treatment Options for Abdominal Aortic Aneurysms Provide More Patients with Access to Minimally Invasive Endovascular Repair
Gore Reports First Patient Treated in Europe using the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface on a Lower Profile Delivery System
21 March 2011 - Lower profile delivery system provides more options for endoluminal bypass
21 March 2011 - Lower profile delivery system provides more options for endoluminal bypass
NewsVIABAHN® Endoprosthesis with Heparin Bioactive Surface Large Diameter Press Release
(92 KB, 1 pages, .pdf)
Gore Recognizes Physicians as “Pioneers in Performance” for Exceptional Work in the Field of Endovascular Therapy
17 February 2009 - Leading practitioners and researchers from around the world commended for expanding treatment options for at-risk patients
17 February 2009 - Leading practitioners and researchers from around the world commended for expanding treatment options for at-risk patients
GORE® Hybrid Vascular Graft Honored as Gold Winner in the 2012 Medical Design Excellence Awards
03 July 2012 - W. L. Gore & Associates (Gore) today announced that the GORE® Hybrid Vascular Graft was awarded Gold Winner in the Implant and Tissue-Replacement Products category of the 2012 Medical Design Excellence Awards (MDEA) competition.
03 July 2012 - W. L. Gore & Associates (Gore) today announced that the GORE® Hybrid Vascular Graft was awarded Gold Winner in the Implant and Tissue-Replacement Products category of the 2012 Medical Design Excellence Awards (MDEA) competition.
Gore Receives Approval from FDA for Unique Patent Foramen Ovale Stroke Study
05 May 2008 - Multinational trial randomizes stroke patients with Patent Foramen Ovale (PFO) to closure with the GORE HELEX Septal Occluder versus medical management
05 May 2008 - Multinational trial randomizes stroke patients with Patent Foramen Ovale (PFO) to closure with the GORE HELEX Septal Occluder versus medical management
New 10 cm GORE® Hybrid Vascular Graft Delivers Unprecedented Versatility
14 November 2012 - Increased Length of Nitinol Reinforced Section Allows for Access to Deeper Vessels, Extends Landing-Zone Positioning Options
14 November 2012 - Increased Length of Nitinol Reinforced Section Allows for Access to Deeper Vessels, Extends Landing-Zone Positioning Options
Gore Announces FDA Approval of Next Evolution of GORE® VIABAHN® Endoprosthesis
17 February 2011 - Lower profile delivery system in the US provides more options for endoluminal bypass
17 February 2011 - Lower profile delivery system in the US provides more options for endoluminal bypass
Gore Receives Health Canada Approval for Removable GORE® VIABIL® Biliary Endoprosthesis
17 January 2011 - New treatment option now available for benign and malignant biliary strictures
17 January 2011 - New treatment option now available for benign and malignant biliary strictures
Gore Receives FDA Approval for Innovative GORE® C3 Delivery System for GORE® EXCLUDER® AAA Endoprosthesis
04 January 2011 - New innovation enables physicians and interventionalists to reposition device for ideal placement in treating abdominal aortic aneurysms.
04 January 2011 - New innovation enables physicians and interventionalists to reposition device for ideal placement in treating abdominal aortic aneurysms.
25cm Longest Length CE Mark Approval Press ReleaseGORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface
(138 KB, 1 pages, .pdf)
VIPER Study Completes Enrollment Press ReleaseGORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface
(106 KB, 1 pages, .pdf)
First Patient GORE® ACUSEAL Vascular Graft Clinical Study Press ReleaseGORE® ACUSEAL Vascular Graft
(122 KB, 1 pages, .pdf)
NewsEXCLUDER® AAA Endoprosthesis Q50 Stent Graft Balloon Catheter Press Release
(115 KB, 2 pages, .pdf)